@misc{indiciae8331afd399af,
  title = {First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials},
  author = {Wu, Q. and Luo, W. and Li, W. and Wang, T. and Huang, L. and Xu, F.},
  year = {2020},
  doi = {10.1101/2020.04.17.046409},
  url = {https://www.biorxiv.org/content/10.1101/2020.04.17.046409v1},
  note = {Source identifier: 10.1101/2020.04.17.046409}
}